TOFATIL 11 SR Tablets – Empowering Patients with Advanced Management for Chronic Inflammatory Conditions.
TOFATIL 11 ER – Tofacitinib 11 MG ER is an oral Janus Kinase (JAK) inhibitor that modulates the immune response by selectively targeting JAK enzymes. By blocking intracellular signaling pathways critical for immune activation,
Tofacitinib helps control:
* Joint inflammation and damage in arthritis.
* Intestinal inflammation in ulcerative colitis.
* Skin and joint manifestations in psoriatic arthritis.
Recommended by specialists:
✅Rheumatologists :- To manage autoimmune disorders such as rheumatoid arthritis, and psoriatic arthritis.
✅Gastroenterologist : To manage moderate to severe ulcerative colitis.
Key benefits of Tofacitinib 11 MG ER Tablets – TOFATIL 11 SR Tablets
✅Extended-Release Formulation: Provides sustained efficacy with once-daily dosing, ensuring improved patient compliance and consistent therapeutic levels.
✅Targeted Action : Specifically inhibits Janus Kinase (JAK) pathways, reducing inflammation at the cellular level while minimizing systemic effects.
✅Versatile Usage : Approved for multiple chronic inflammatory conditions, including rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis.
✅Rapid Onset : Demonstrates faster symptom relief compared to conventional therapies for inflammatory diseases.
Indications –
✅ Rheumatoid Arthritis (RA) (moderate to severe)
✅ Psoriatic Arthritis (PsA)
✅ Ulcerative Colitis (UC) (moderate to severe)
✅Ankylosing Spondylitis (AS) (investigational in some cases)